Related references
Note: Only part of the references are listed.The Membrane Mimetic Affects the Spatial Structure and Mobility of EGFR Transmembrane and Juxtamembrane Domains
Konstantin S. Mineev et al.
BIOCHEMISTRY (2015)
Cell-free expression of functional receptor tyrosine kinases
Wei He et al.
SCIENTIFIC REPORTS (2015)
Advances in the use of nanoscale bilayers to study membrane protein structure and function
Ketan Malhotra et al.
BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS, VOL 30, ISSUE 1 (2014)
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
Alexis B. Cortot et al.
EUROPEAN RESPIRATORY REVIEW (2014)
A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment
Hongzheng Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Autophosphorylation activation and inhibition by curcumin of the epidermal growth factor receptor reconstituted in liposomes
Samah Doumiati et al.
JOURNAL OF MOLECULAR RECOGNITION (2012)
Update on HER1–3 in Advanced Non–Small-Cell Lung Cancer
Leora Horn et al.
Journal of Thoracic Oncology (2012)
Molecular pathology of lung cancer: key to personalized medicine
Liang Cheng et al.
MODERN PATHOLOGY (2012)
The Cell-Free Integration of a Polytopic Mitochondrial Membrane Protein into Liposomes Occurs Cotranslationally and in a Lipid-Dependent Manner
Ashley R. Long et al.
PLOS ONE (2012)
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
Geoffrey R. Oxnard et al.
CLINICAL CANCER RESEARCH (2011)
Comparing the Epidermal Growth Factor Interaction with Four Different Cell Lines: Intriguing Effects Imply Strong Dependency of Cellular Context
Hanna Bjorkelund et al.
PLOS ONE (2011)
Regulation of human EGF receptor by lipids
Unal Coskun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non-Small-Cell Lung Cancer
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
D. Ercan et al.
ONCOGENE (2010)
Isolation, Characterization, and Stability of Discretely-Sized Nanolipoprotein Particles Assembled with Apolipophorin-III
Nicholas O. Fischer et al.
PLOS ONE (2010)
The Juxtamembrane Region of EGFR Takes center stage
Stevan R. Hubbard
CELL (2009)
Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment
Natalia Jura et al.
CELL (2009)
Ligand-induced ErbB receptor dimerization
Mark A. Lemmon
EXPERIMENTAL CELL RESEARCH (2009)
Mechanisms of tumor resistance to EGFR-targeted therapies
Elizabeth A. Hopper-Borge et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
Characterization and Purification of Polydisperse Reconstituted Lipoproteins and Nanolipoprotein Particles
Craig D. Blanchette et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2009)
Hydrogen Production by a Hyperthermophilic Membrane-Bound Hydrogenase in Water-Soluble Nanolipoprotein Particles
Sarah E. Baker et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2009)
The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain
Monica Red Brewer et al.
MOLECULAR CELL (2009)
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
A. F. Gazdar
ONCOGENE (2009)
Functional and structural stability of the epidermal growth factor receptor in detergent micelles and phospholipid nanodiscs
Li-Zhi Mi et al.
BIOCHEMISTRY (2008)
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Jeffrey A. Engelman et al.
CLINICAL CANCER RESEARCH (2008)
ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer
David F. Stern
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2008)
Different apolipoproteins impact nanolipoprotein particle formation
Brett A. Chromy et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2007)
Targeting HER proteins in cancer therapy and the role of the non-target HER3
A. C. Hsieh et al.
BRITISH JOURNAL OF CANCER (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations
Marianela Perez-Torres et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth
Lily Yen et al.
CANCER RESEARCH (2006)
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
Marissa N. Balak et al.
CLINICAL CANCER RESEARCH (2006)
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Rita Nahta et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Trastuzumab and antiestrogen therapy -: Focus on mechanisms of action and resistance
A Ocaña et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2006)
Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface
JP Dawson et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Comparison of ELISA-based tyrosine kinase assays for screening EGFR inhibitors
E Varkondi et al.
JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION (2005)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
The biology of epidermal growth factor receptor in lung cancer
GV Scagliotti et al.
CLINICAL CANCER RESEARCH (2004)
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors
AW Burgess et al.
MOLECULAR CELL (2003)
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
T Holbro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The deaf and the dumb: the biology of ErbB-2 and ErbB-3
A Citri et al.
EXPERIMENTAL CELL RESEARCH (2003)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
HS Cho et al.
NATURE (2003)
The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors
TPJ Garrett et al.
MOLECULAR CELL (2003)
Effect of membrane fluidity on tyrosine kinase activity of reconstituted epidermal growth factor receptor
GX Ge et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Share Paper
